NeuroSense (NRSN) is scheduled for a Type C meeting with the FDA to discuss the design of its upcoming Phase 3 clinical trial for PrimeC, a potential treatment for Amyotrophic Lateral Sclerosis, or ALS. The FDA Type C meeting, scheduled for November 6, will focus on finalizing the design of the Phase 3 trial, a pivotal step toward securing approval for the drug. NeuroSense will also review its readiness for a future New Drug Application submission, ensuring its regulatory strategy aligns with the FDA’s requirements. In parallel, NeuroSense plans to submit its regulatory dossier to Health Canada in Q2 2025, with a regulatory decision anticipated by Q1 2026. The company estimates the potential market opportunity for PrimeC in Canada alone to be approximately $100M-$150M in annual revenue. This decision follows the recommendations of Canadian regulatory experts and recent clinical findings, which demonstrated that PrimeC significantly reduced disease progression and improved survival rates by 43% compared to placebo, highlighting its potential as a breakthrough therapy for ALS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NRSN:
- NeuroSense’s PrimeC Shows Potential in ALS Treatment
- NeuroSense’s PrimeC shows microRNA improvement in ALS
- NeuroSense Targets Key ALS Drug Market in Canada
- NeuroSense Targets Early ALS Drug Approval in Canada
- NeuroSense to file for early commercialization of ALS treatment in Canada
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
